News Sentiment

NPCE sentiment intelligence

Neuropace Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 17.11 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+6.0% over one week, +9.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction 6.0% Price confirming higher
Trend fit Trend active 9.4% over four weeks
Fair value 51.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 38
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
TradingView 6
Stock Titan 6
TradingKey 6
MarketBeat 3
Finviz 2
Stock Traders Daily 2
StockStory 2

Event Lens

What the news is about

Classified themes
Earnings 25
Market update 22
Analyst action 3
Regulatory and legal 3
Balance sheet 1
Deals and strategy 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
TradingView Direct company coverage

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

NeuroPace (NPCE) stock is recommended for retention due to anticipated growth from its RNS System adoption, expanding referral networks, and AI innovations, with potential long-term benefits from an IGE indication. However, profitability may face near-term pressure from increased

Tone
Positive 65/100
Event
Market update
Published
15 Jul 2026 14:13
Source
TradingView
MarketBeat Direct company coverage

NeuroPace (NASDAQ:NPCE) Shares Down 5.8% - What's Next?

NeuroPace (NASDAQ:NPCE) shares dropped 5.8% on Tuesday, trading as low as $16.23 on significantly below-average volume. Despite beating recent quarterly earnings and revenue expectations, the company reported negative margins and has a high debt-to-equity ratio of 4.08. Analyst s

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 18:13
Source
MarketBeat
Quartr Direct company coverage

NeuroPace (NPCE) Proxy filing Summary

NeuroPace (NPCE) has scheduled its Annual Meeting for June 5, 2026, to be held virtually, where stockholders of record as of April 9, 2026, will vote on the election of two Class II directors, Lisa Andrade and Scott Huennekens, and the ratification of PricewaterhouseCoopers LLP a

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 22:40
Source
Quartr
MarketBeat Direct company coverage

NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of "Moderate Buy" by Brokerages

NeuroPace, Inc. (NASDAQ:NPCE) has received a "Moderate Buy" consensus rating from eight analysts, with an average 12-month price target of $18.83. The company recently surpassed quarterly earnings estimates, reporting an EPS of -$0.13 against an expected -$0.19 and revenue slight

Tone
Positive 66/100
Event
Earnings
Published
10 Jul 2026 08:39
Source
MarketBeat
Simply Wall Street Direct company coverage

At US$17.80, Is It Time To Put NeuroPace, Inc. (NASDAQ:NPCE) On Your Watch List?

NeuroPace, Inc. (NASDAQ:NPCE) has seen a significant share price rise of 39% recently but is currently trading at US$17.80, which is 27% overvalued compared to its intrinsic value of $14.05. Despite this, the company's future outlook appears bright with expected profit growth of

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 10:11
Source
Simply Wall Street
TradingView Direct company coverage

Price to earnings forward of Neuropace, Inc. – NASDAQ:NPCE

This article provides financial information for Neuropace, Inc. (NASDAQ:NPCE), specifically focusing on its forward price-to-earnings ratio. It seems to be a financial data page from TradingView, which lists various financial metrics and resources related to the company. The cont

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 04:39
Source
TradingView
Finviz Direct company coverage

NPCE - NeuroPace Inc Short Interest

This article provides detailed financial and stock performance data for NeuroPace Inc (NPCE). It covers various metrics including short interest, market capitalization, income, sales, P/E ratios, insider and institutional ownership, and year-over-year growth figures. The data als

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 08:11
Source
Finviz
Finviz Direct company coverage

NPCE - NeuroPace Inc Website Traffic and Mobile Apps Usage

This article provides a comprehensive overview of NeuroPace Inc. (NPCE), a medical device company specializing in epilepsy treatments. It details the company's financial metrics, stock performance, analyst recommendations, and a chronological list of significant news and events,

Tone
Neutral 50/100
Event
Analyst action
Published
03 Jul 2026 04:39
Source
Finviz
Moomoo Direct company coverage

NeuroPace | 4: Statement of changes in beneficial ownership of securities-Director Fischer Frank M

This article announces a statement of changes in beneficial ownership of securities for Director Fischer Frank M at NeuroPace (NPCE), as filed with the SEC on June 6. It also includes extensive disclaimers from Moomoo regarding the informational nature of the content and the risk

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 04:39
Source
Moomoo
Stock Traders Daily Direct company coverage

Price-Driven Insight from (NPCE) for Rule-Based Strategy

This article provides a price-driven analysis of Neuropace Inc. (NPCE) using AI models to determine trading strategies. It highlights a strong near-term sentiment that could lead to a neutral mid-term and positive long-term bias, and outlines specific institutional trading strate

Tone
Positive 67/100
Event
Market update
Published
28 Jun 2026 00:10
Source
Stock Traders Daily
Insider Monkey Direct company coverage

NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant™

NeuroPace, Inc. (NASDAQ:NPCE) announced FDA approval for its ECoG Assistant™, an AI-driven tool designed to enhance epilepsy care by analyzing long-term intracranial EEG data. The technology, built on extensive epileptologist-labeled records, aims to improve efficiency in data re

Tone
Positive 91/100
Event
Regulatory and legal
Published
27 Jun 2026 11:31
Source
Insider Monkey
TradingView Direct company coverage

NeuroPace, Inc. Actuals & Estimates (NASDAQ:NPCE)

This article provides an overview of NeuroPace, Inc. (NASDAQ: NPCE) stock, including its current price, market capitalization, historical highs and lows, and analyst forecasts. It also details recent financial performance, such as earnings per share and revenue for past quarters,

Tone
Positive 65/100
Event
Earnings
Published
26 Jun 2026 02:09
Source
TradingView
Stock Titan Direct company coverage

NeuroPace (NPCE) CMO has shares withheld to cover RSU tax bill

NeuroPace Inc.'s Chief Medical Officer, Martha Morrell, had 335 shares of common stock withheld on June 24, 2026, to cover tax obligations related to a restricted stock unit vesting. These shares were disposed of at $16.22 per share. Following this transaction, Morrell directly h

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 20:09
Source
Stock Titan
TradingView Direct company coverage

NPCE Forecast — Price Target — Prediction for 2027

This article provides an overview of Neuropace, Inc. (NPCE) stock, including its current price, analyst forecasts, and recent financial performance. It highlights that 8 analysts offer 1-year price targets, with a max estimate of $22.00 and a min estimate of $18.00. The company's

Tone
Positive 63/100
Event
Analyst action
Published
25 Jun 2026 17:09
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 4 Neuropace Inc For: 22 June By Investing.com

This article provides details about a Form 4 filing for Neuropace Inc. on June 22 and mentions the company's stock symbol NPCE, which saw a slight decrease. It is a very brief report, likely indicating an insider transaction or change in ownership, without providing further speci

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 21:38
Source
Investing.com Nigeria
Stock Titan Direct company coverage

NeuroPace (NPCE) director granted 789 shares as quarterly fee award

NeuroPace director Uri Geiger was awarded 789 shares of common stock at $15.63 per share as a quarterly fee, in lieu of a cash retainer, under the company's non-employee director compensation policy. Following this award, Geiger directly holds 18,537 NeuroPace shares, with an add

Tone
Neutral 50/100
Event
Balance sheet
Published
22 Jun 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

NeuroPace (NPCE) director Rakhi Kumar awarded 989 shares as quarterly retainer

NeuroPace Inc. director Rakhi Kumar was granted 989 common shares as a quarterly retainer, valued at $15.63 per share. This stock award is part of the company's non-employee director compensation policy and increases Kumar's direct holdings to 23,039 NeuroPace common shares. The

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] NeuroPace Inc Insider Trading Activity

NeuroPace Inc. director Frank M. Fischer reported the acquisition of 1,467 shares of Common Stock on June 19, 2026, as detailed in a recent Form 4 filing. These shares were awarded as part of the company's non-employee director compensation policy, given in lieu of quarterly cash

Tone
Neutral 50/100
Event
Deals and strategy
Published
22 Jun 2026 20:39
Source
Stock Titan
www.marketscreener.com Direct company coverage

NeuroPace, Inc.(NasdaqGM:NPCE) added to S&P Healthcare Equipment Select Industry Index

NeuroPace, Inc. (NasdaqGM:NPCE), a medical device company specializing in epilepsy treatment, has been added to the S&P Healthcare Equipment Select Industry Index. This news follows recent company updates, including FDA approval for its ECoG Assistant and the submission of a next

Tone
Positive 71/100
Event
Regulatory and legal
Published
22 Jun 2026 01:10
Source
www.marketscreener.com
TradingKey Direct company coverage

Neuropace Inc (NPCE) Financial Health: Profitability & Balance Sheet Analysis

Neuropace Inc (NPCE) has a weak financial health score of 6.53, ranking 150 out of 203 in its industry, with average operating efficiency. Its latest quarterly revenue saw a 2.02% year-over-year decrease to $22.07 million, and net profit also fell by 1.52% year-over-year. Key fin

Tone
Negative 31/100
Event
Earnings
Published
18 Jun 2026 10:39
Source
TradingKey
TradingKey Direct company coverage

Neuropace Inc (NPCE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Neuropace Inc (NPCE), detailing its price momentum score of 6.58 and its current trading range between a resistance level of $16.91 and a support level of $14.14. It examines various technical indicators, such as MACD, RSI, and moving

Tone
Negative 40/100
Event
Market update
Published
18 Jun 2026 03:40
Source
TradingKey
TradingKey Direct company coverage

Neuropace Inc (NPCE) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Neuropace Inc (NPCE), noting its current valuation score is 9.40, ranking 21st in its industry. It highlights the company's P/E ratio of -23.50, which is significantly below its recent high. The report also states that relevant P/B, P

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 02:40
Source
TradingKey
TradingKey Direct company coverage

Neuropace Inc (NPCE) Institutional Confidence

Neuropace Inc (NPCE) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. Institutional investors hold 99.26% of shares, a 7.21% increase quarter-over-quarter. James Simons is the largest institutional shareholder, ho

Tone
Positive 66/100
Event
Market update
Published
18 Jun 2026 02:40
Source
TradingKey
TradingKey Direct company coverage

Neuropace Inc (NPCE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article focuses on the revenue breakdown for NeuroPace Inc (NPCE), indicating that relevant data for business segments and regional profit contributions have not yet been disclosed by the company. It briefly presents the company's United States revenue at $99.99 million with

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 01:40
Source
TradingKey
Stock Traders Daily Direct company coverage

(NPCE) Price Dynamics and Execution-Aware Positioning

This article analyzes Neuropace Inc. (NPCE) stock dynamics, highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents AI-generated trading strategies including position trading, momentum breakout, and risk hedging, with specific entry points, targe

Tone
Positive 72/100
Event
Guidance
Published
16 Jun 2026 23:10
Source
Stock Traders Daily
TradingKey Direct company coverage

Neuropace Inc (NPCE) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Neuropace Inc (NPCE), highlighting its current earnings forecast score of 8.50 and an average analyst price target of $18.00. Analysts largely recommend a "Buy" for NPCE, with expectations for future revenue and EPS also detailed. Th

Tone
Positive 65/100
Event
Earnings
Published
16 Jun 2026 22:10
Source
TradingKey
MSN Direct company coverage

NeuroPace (NPCE) down 0.6% since last earnings report: Can it rebound?

This article discusses the recent performance of NeuroPace (NPCE) stock, which has dropped 0.6% since its last earnings report. It raises the question of whether the stock can rebound from this decline. The content of the article would likely delve into factors influencing NPCE's

Tone
Negative 39/100
Event
Earnings
Published
15 Jun 2026 16:39
Source
MSN